Immunogenicity and Safety of the Investigational Inactivated, Split-Virion Influenza Vaccine 15 microg Administered by the Intradermal Route in Comparison with the Intramuscular Reference Vaccine Vaxigrip in 50 to 59 Years old Adults.

Trial Profile

Immunogenicity and Safety of the Investigational Inactivated, Split-Virion Influenza Vaccine 15 microg Administered by the Intradermal Route in Comparison with the Intramuscular Reference Vaccine Vaxigrip in 50 to 59 Years old Adults.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Aug 2011

At a glance

  • Drugs Influenza virus vaccine (Primary) ; Influenza virus vaccine
  • Indications Influenza virus infections
  • Focus Pharmacodynamics
  • Sponsors sanofi pasteur
  • Most Recent Events

    • 02 Aug 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top